Table 1

Summary of baseline patient and disease characteristics for DISCOVER-1 patients by TNFi status

All patientsTNFi-naiveTNFi-experienced
Randomised and treated patients, N381263 (69%)118 (31%)
Age (years), mean (SD)48.4 (11.4)47.6 (11.7)50.2 (10.5)
Sex, n (%)
 Male195 (51.2)133 (50.6)62 (52.5)
 Female186 (48.8)130 (49.4)56 (47.5)
Weight (kg), mean (SD)86.0 (18.8)86.3 (18.8)85.4 (18.7)
BMI (kg/m2), mean (SD)29.8 (5.8)29.8 (6.0)29.9 (5.5)
 Normal (<25), n (%)79 (20.7)58 (22.1)21 (17.8)
 Overweight (≥25 and<30)136 (35.7)95 (36.1)41 (34.7)
 Obese (≥30), n (%)166 (43.6)110 (41.8)56 (47.5)
PsA disease duration (years), mean (SD)6.8 (6.6)5.6 (6.2)9.4 (6.9)
Joint counts, mean (SD)
 Swollen (0–66)9.8 (7.6)9.5 (7.0)10.6 (8.7)
 Tender (0–68)19.3 (14.0)17.9 (13.2)22.4 (15.3)
Psoriasis disease duration (years), mean (SD)17.0 (12.7)16.4 (13.3)18.3 (11.1)
Psoriasis, n (%)
 ≥3% BSA281 (73.9)*191 (72.9)†90 (76.3)
 IGA ≥2 and ≥3% BSA249 (65.5)*166 (63.4)†83 (70.3)
HAQ-DI (0–3), mean (SD)1.2 (0.6)1.1 (0.6)1.4 (0.7)
CRP (mg/dL), mean (SD)1.4 (2.0)1.1 (1.8)1.9 (2.3)
DMARD use at baseline, n (%)247 (64.8)160 (60.8)87 (73.7)
 Methotrexate211 (55.4)133 (50.6)78 (66.1)
 Other36 (9.4)27 (10.3)9 (7.6)
  • *N=380.

  • †N=262.

  • BMI, body mass index; BSA, body surface area; CRP, C reactive protein; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment Questionnaire-Disability Index; IGA, Investigator’s Global Assessment of psoriasis; PsA, psoriatic arthritis; TNFi, tumor necrosis factor-inhibitor.